

## T Cell TransAct™

Efficient T cell activation and expansion

# Your new solution for T cell activation

#### What is T Cell TransAct<sup>™</sup>?

This ready-to-use reagent provides an innovative method for physiological activation and expansion of human T cells.

T Cell TransAct is a colloidal polymeric nanomatrix conjugated to humanized recombinant CD3 and CD28 agonists ensuring successful activation of resting T cells from hematological cell populations (e.g. PBMCs or enriched T cell populations) without the involvement of CD4 or CD8.

MACS<sup>®</sup> GMP T Cell TransAct is manufactured and controlled under ISO 13485 requirements. It is designed following the recommendations of USP <1043> on ancillary materials. In the US, a master file is held with the FDA for IND applications with Product Quality Certificate available via our website.



**Figure 1:** T Cell TransAct is in suspension when added to cell culture for polyclonal T cell stimulation.

## T cell activation made simple and convenient



GMP

#### Practical application

- Volumetric dosage
- Ready-to-use Removal by simple washing
- , ,

#### **Robust stimulation**

- Highest cell viability
- Physiological and stable stimulation

#### **Convenient compatibility**

- Available for research and
- GMP T cell workflows
- Optimized for CART cell production
- on the CliniMACS Prodigy<sup>®</sup> • Can be sterile filtered





# Efficient T cell activation and expansion

#### **Effective stimulation**

T Cell TransAct<sup>™</sup> enables optimal T cell activation with a polymeric nanomatrix. The activation efficiency is comparable to larger activation beads. T cell activation made simple and convenient.



**Figure 2:** Comparison of activation efficiency at day two between T Cell TransAct and competitor product according to the activation markers CD69 and CD25. After two days, T Cell TransAct-activated cells are comparable to bead-activated cells.

#### **High expansion**

When striving for robust and reliable T cell proliferation, T Cell TransAct enables serum-free T Cell cultivation while maintaining consistently high cell expansion.



**Figure 3:** Comparable results of T cell expansion after stimulation with T Cell TransAct or competitor product in TexMACS Medium without human AB serum supplementation.

#### **Excellent proliferation**

Proliferation of T cells is observed after stimulation with T Cell TransAct. Equal amounts of proliferation are observed when compared to bead-based stimulation methods.



Figure 4: After seven days, proliferation of T Cell TransAct-activated cells is equal to bead-activated cells. T cells were cultivated in TexMACS<sup>™</sup> Medium supplemented with IL-7 and IL-15.

#### T cell phenotype

Generating CAR T cells requires a stable T cell phenotype. T cells activated with T cell TransAct and subsequently expanded with IL-7 and IL-15, display a phenotype of early differentiated T cells.



**Figure 5:** T cells were activated with T Cell TransAct and expanded for 14 days in TexMACS Medium supplemented with IL-7 and IL-15. More than 85% were stem memory T cells and central memory T cells.

## Setting the stage for automated production of engineered T cells

#### **Optimal design for CliniMACS Prodigy®**

MACS<sup>®</sup> GMP T Cell TransAct<sup>™</sup> is tailor made for the CliniMACS Prodigy.

- Maximum activation capacity for up to 1×10<sup>8</sup> cells
- 1 vial of MACS GMP T Cell TransAct per T cell transduction (TCT) production run

MACS GMP T Cell TransAct allows potent polyclonal T cell activation prior gene modification without the need for feeder cells.



**Figure 6:** Isolated T cells were activated with MACS GMP T Cell TransAct and transduced with lentivirus (B) or retrovirus (D). Transduction of T cells with GFP vector resulted in strong GFP expression eleven days after gene modification (B, D). Untransduced T cells show no expression of GFP (A, C).

#### Cell expansion in serum-free media

Clinical-scale expansion of transduced T cells is effective under cultivation conditions with or without human AB serum (fig. 7A and B). The synergy between MACS GMP T Cell TransAct, TexMACS<sup>™</sup> Medium and our MACS GMP Cytokines delivers an optimal final engineerd cell product independent of serum addition (fig. 7C).



**Figure 7:** Enriched CD4<sup>+</sup> and CD8<sup>+</sup> T cells were stimulated with MACS GMP T Cell TransAct and expanded in a TCT process with 3% human AB serum or serum-free. Cell count (A) and viability (B) of cultured cells were measured at different time points. Cellular composition was determined in starting material, enriched population and in the final expanded product (C).

## MACS<sup>®</sup> GMP T Cell TransAct<sup>™</sup>- Large Scale



#### Scale-up your T cell expansion

MACS GMP T Cell TransAct - Large Scale is optimized for the activation of high cell numbers. It is tailormade for the application on the CliniMACS Prodigy<sup>®</sup> in combination with the tubing set including the large cultivation chamber.

- Efficient T cell activation and expansion for high cell numbers
- Optimized to activate and expand up to 4×10<sup>8</sup> enriched T cells
- One vial of MACS GMP T Cell TransAct Large Scale is sufficient for one T cell transduction large-scale production run



Figure 8: Enriched CD4<sup>+</sup>/CD8<sup>+</sup> T cells were automatically expanded

right c. Einfeld CD4 (CD5) reals were automatically expanded on the CliniMACS Prodigy after polyclonal stimulation with MACS GMP T Cell TransAct, standard or Large Scale. Either the standard-scale chamber (black, n=4) or the large-scale chamber (orange, n=6) was used for culture. Cell cultivation was monitored at different time points to determine cell number (A) and viability (B). On average, a total cell number of  $2.1\times10^{10}$  cells was reached using the large-scale chamber and MACS GMP T Cell TransAct - Large Scale in comparison to  $6.5\times10^{9}$ cells expanded in the standard-scale chamber. The cellular composition of the enriched fraction was analyzed by flow cytometry on the MACSQuant<sup>®</sup> Analyzer 10. Frequencies of T cell phenotypes among viable CD45<sup>+</sup> cells were determined for the final cell product (C).

## **Translational solutions for T cell activation**

### Research

#### ACTIVATION

### Clinical



#### See the CliniMACS Prodigy Process in action!

Generate gene-modified T cells in a simple and automated fashion. Easy to use, this unique process will surely change the way you work.

miltenyibiotec.com/tct

### miltenyibiotec.com



**Miltenyi Biotec** 

Germany/Austria Miltenyi Biotec B.V. & Co. KG Friedrich-Ebert-Straße 68 51429 Bergisch Gladbach Germany Phone +49 2204 8306-0 Fax +49 2204 85197 macsde@miltenyi.com

#### USA/Canada

Miltenyi Biotec Inc. 2303 Lindbergh Street Auburn, CA 95602, USA Phone 800 FOR MACS Phone +1 530 888 8871 Fax +1 877 591 1060 macsus@miltenyi.com

#### Australia

Miltenyi Biotec Australia Pty. Ltd. Unit 11, 2 Eden Park Drive Macquarie Park, NSW 2113 Australia Phone +61 2 8877 7400 Fax +61 2 9889 5044 macsau@miltenyi.com

#### Benelux

Miltenyi Biotec B.V. Sandifortdreef 17 2333 ZZ Leiden The Netherlands macsnl@miltenyi.com **Customer service** The Netherlands Phone 0800 4020120 Fax 0800 4020100 **Customer service Belgium** 

Phone 0800 94016 Fax 0800 99626 Customer service Luxembourg Phone 800 24971 Fax 800 24984

#### China

Miltenyi Biotec Technology & Trading (Shanghai) Co., Ltd. Room 401 No. 1077, Zhangheng Road Pudong New Area 201203 Shanghai, P.R. China Phone +86 21 6235 1005 Fax +86 21 6235 0953 macscn@miltenyi.com

#### France

Miltenyi Biotec SAS 10 rue Mercoeur 75011 Paris, France Phone +33 1 56 98 16 16 Fax +33 1 56 98 16 17 macsfr@miltenyi.com

#### Italy

Miltenyi Biotec S.r.l. Via Paolo Nanni Costa, 30 40133 Bologna Italy

Phone +39 051 6 460 411 Fax +39 051 6 460 499 macsit@miltenyi.com

#### Japan

Miltenyi Biotec K.K. NEX-Eitai Building 5F 16-10 Fuyuki, Koto-ku Tokyo 135-0041, Japan Phone +81 3 5646 8910 Fax +81 3 5646 8911 macsjp@miltenyi.com

**Nordics and Baltics** Miltenyi Biotec Norden AB Medicon Village Scheeletorget 1 223 81 Lund Sweden macsse@miltenyi.com Customer service Sweden Phone 0200 111 800 **Customer service Denmark** Phone 80 20 30 10 **Customer service** Norway, Finland, Iceland, and Baltic countries Phone +46 46 280 72 80

#### Singapore

Miltenyi Biotec Asia Pacific Pte Ltd 438B Alexandra Road, Block B Alexandra Technopark

#06-01 Singapore 119968 Phone +65 6238 8183 Fax +65 6238 0302 macssg@miltenyi.com

#### South Korea

Miltenyi Biotec Korea Co., Ltd. Arigi Bldg. 8F 562 Nonhyeon-ro Gangnam-gu Seoul 06136, South Korea Phone +82 2 555 1988 Fax +82 2 555 8890 macskr@miltenyi.com

#### Spain

Miltenyi Biotec S.L. C/Luis Buñuel 2 Ciudad de la Imagen 28223 Pozuelo de Alarcón (Madrid) Spain Phone +34 91 512 12 90 Fax +34 91 512 12 91 macses@miltenyi.com

#### Switzerland

Miltenyi Biotec Swiss AG Gibelinstrasse 27 4500 Solothurn Switzerland Phone +41 32 623 08 47 Fax +49 2204 85197 macsch@miltenyi.com

#### **United Kingdom**

Miltenyi Biotec Ltd. Almac House, Church Lane Bisley, Surrey GU24 9DR, UK Phone +44 1483 799 800 Fax +44 1483 799 811 macsuk@miltenyi.com

www.miltenyibiotec.com

30-118-046.04

Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS

Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.

CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS Prodigy, MACS, TexMACS, TransAct, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.